Evergreen Capital Management LLC Sells 1,078 Shares of Eli Lilly and Company $LLY

Key Points

• Evergreen Capital Management LLC has reduced its stake in Eli Lilly and Company by 10.5%, selling 1,078 shares during the first quarter, leaving them with 9,210 shares valued at approximately $7.6 million.
• The company recently reported $6.31 earnings per share, exceeding expectations of $5.59, while revenues for the quarter reached $15.56 billion, significantly higher than the anticipated $14.40 billion.
• Insider transactions included CEO David Ricks purchasing 1,632 shares at an average price of $644.77 each, reflecting confidence in the company amidst a high percentage of institutional ownership at 82.53%.

Evergreen Capital Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,210 shares of the company's stock after selling 1,078 shares during the quarter. Evergreen Capital Management LLC's holdings in Eli Lilly and Company were worth $7,606,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Driehaus Capital Management LLC grew its stake in shares of Eli Lilly and Company by 73.2% during the 1st quarter. Driehaus Capital Management LLC now owns 1,675 shares of the company's stock worth $1,383,000 after acquiring an additional 708 shares during the period. Palo Alto Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 2.9% during the first quarter. Palo Alto Wealth Advisors LLC now owns 712 shares of the company's stock valued at $588,000 after purchasing an additional 20 shares during the last quarter. WPG Advisers LLC bought a new position in Eli Lilly and Company during the first quarter worth about $335,000. TD Capital Management LLC boosted its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the period. Finally, Tema Etfs LLC increased its stake in shares of Eli Lilly and Company by 70.0% in the first quarter. Tema Etfs LLC now owns 12,138 shares of the company's stock worth $10,025,000 after purchasing an additional 4,998 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.1%

Shares of NYSE:LLY opened at $732.41 on Friday. The firm has a fifty day moving average price of $748.68 and a two-hundred day moving average price of $786.10. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $969.65. The company has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 earnings per share. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Leerink Partners restated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Finally, Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Insider Activity

In related news, CEO David A. Ricks bought 1,632 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.